Teva Copaxone sales fall 12%; NICE says no to new Revlimid use; Valeant cuts forecast;

@FiercePharma: ICYMI: Novartis reports high Bexsero uptake as it pushes ahead in open market. FierceVaccines story | Follow @FiercePharma

@TracyStaton: On $PFE, the market's focus is on EPS beat. 58 cents vs. expected 57. Shares up 1.3% pre-market. Release | Follow @TracyStaton

@EricPFierce: Run-ins with the FDA continue to chew up the earnings at India's Ranbaxy. FiercePharmaManufacturing story | Follow @EricPFierce

@CarlyHFierce: ICYMI: This week's full issue of FiercePharmaMarketing. Report | Follow @CarlyHFierce

> Teva Pharmaceutical Industries ($TEVA) reported that Q2 revenue was up 2% to $5 billion but sales of its key product Copaxone were off 12%. Release

> Teva ($TEVA) shareholders approved all the board members up for reappointment over objections by activist shareholder Benny Landa. Story

> U.K. cost watchdog, the National Institute for Health and Clinical Excellence (NICE) is not recommending use of Celgene's ($CELG) Revlimid for treatment of multiple myeloma following one prior treatment with Johnson & Johnson's ($JNJ) Velcade. Story

> Pain drug specialist Endo International raised its forecast after its Q2 profit came in higher than expected. Story

> Valeant Pharmaceuticals ($VRX), which is pursuing a hostile takeover of Allergan ($AGN), has cut its 2014 earnings forecast. Story

Medical Device News

@FierceMedDev: Editor's Corner from @HollmerMark: In Q2, diagnostics venture investment showed some signs of life. Article | Follow @FierceMedDev

@StacyALawrence: Edwards stock surges on strong sales, profits due to legal settlement. Article | Follow @StacyALawrence

@VarunSaxena2: Johnson & Johnson to call for voluntary return of morcellators. WSJ story | Follow @VarunSaxena2

@MichaelGFierce: Scientists test a nanoparticle "alarm clock" to awaken immune systems put to sleep by cancer. Release | Follow @MichaelGFierce

@EmilyWFierce: Boston Scientific wins first vaginal mesh case to go to trial. Article | Follow @EmilyWFierce

> FDA advisory panel to consider PMA of TissuGlu surgical adhesive. Article

> Ablatherm ultrasound prostate cancer treatment rebuffed by FDA panel. More

> Fat freezer Zeltiq turns a surprise profit and climbs almost 30%. Story

Biotech News

@FierceBiotech: Nominations are open for our 2014 Women in Biotech report. More | Nomination form | Follow @FierceBiotech

@JohnCFierce: Love this stuff--Sanofi, Regeneron seize a regulatory shortcut in blockbuster PCSK9 race with Amgen. Story | Follow @JohnCFierce

@DamianFierce: Just wait until $GALT finds out what people on Friendster are saying. Story via Yahoo! Finance | Follow @DamianFierce

@EmilyMFierce: Merck aims to boost HPV vaccination rates amid lagging numbers. Story | Follow @EmilyMFierce

> Cold Genesys rakes in $13.6M for its cancer-fighting virus. News

> AstraZeneca dials up its immuno-oncology focus with blockbuster hopes. Article

> Gene therapy biotech Avalanche banks $102M in an up-sized IPO. Story

Vaccines News

> Kenya study reveals new malaria vaccine targets. More

> Flu season should return Sanofi to double-digit vaccines growth, CEO says. Item

> Novartis reports high Bexsero uptake as it pushes ahead in open market. Story

> Merck aims to boost HPV vaccination rates amid lagging numbers. Article

> Pfizer finally lands vaccines bulk-up with $635M Baxter buy. News

Pharma Manufacturing News

> Pfizer buys a portion of a vaccine plant from Baxter, J&J sells a vax facility to PaxVax. Item

> Hospira's Rocky Mount plant meets FDA goals, but one in India does not. Article

> Ranbaxy rings up another loss as regulatory problems chew away profits. Story

> Spectacular warehouse burglary left extensive collateral damage for Eli Lilly. Article

> Manufacturing takes it on the chin in Amgen cuts. More

And Finally... Statins, widely prescribed to lower blood cholesterol, may also help wounds heal after surgery, a new study says. Story (sub. req.)

Suggested Articles

An online pharmacy has again criticized FDA action after tipping off regulators to the existence of a dangerous impurity in Zantac and other antacids.

A group of senators is asking the FTC to take a careful look at pharma mergers given the cost of drugs in the U.S.

Life’s been tough for J&J's prostate cancer med Erleada in its battle with Pfizer-Astellas’ Xtandi. A new FDA nod could help level the playing field.…